Austria expects “sufficient” vaccines

0 0
Read Time:1 Minute, 27 Second

Austria expects to receive a sufficient share of the vaccine doses secured across the EU in the discussion about ordering more vaccines in Europe. “The contract of Biontech and Pfizer includes 200 million doses already ordered by the EU-27 and another option of 100 million doses for which the EU-27 orders are in preparation. All EU countries will get their share secured,” Special Representative Clemens Martin Auer said yesterday.

“These contracts stipulate that individual EU countries can only conclude individual contracts with manufacturers such as Biontech once the large EU contract has been exhausted. Specifically for Biontech, this means that once the 200 plus 100 million doses have all been finally ordered, further individual contracts could be concluded depending on a country’s needs,” explained Auer, who is co-chairman of the EU steering group for the joint purchase of CoV vaccines for the EU-27.

Five additional contracts already concluded
“Austria assumes that the secured contractual share will be sufficient, because five further supply contracts have already been concluded,” Auer said in the health ministry statement provided to APA. Two other vaccines are about to receive marketing authorization: Moderna will receive marketing authorization at the beginning of January (total EU volume 160 million doses), and marketing authorization for AstraZeneca is expected at the end of January or in February (total EU volume 300 million doses).

“The Ministry of Health has developed its vaccination plan on the basis of these expected deliveries, which are always partial deliveries spread over the first three quarters of 2021,” Auer assured. This in turn provides for the roll-out of the vaccinations to the nursing homes to begin with the first partial deliveries from Biontech.

hp, Source: ORF.at/agencies/oicture: pixabay.com

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

This post has already been read 429 times!

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *